%	O
%	O
TITLE	O

Association	O
of	O
HPV	O
infections	O
with	O
second	O
primary	O
tumors	O
in	O
early	O
-	O
staged	O
oral	O
cavity	O
cancer	O
.	O

%	O
%	O
ABSTRACT	O

The	O
infection	O
of	O
human	O
papilloma	O
virus	O
(	O
HPV	O
)	O
has	O
been	O
reported	O
in	O
head	O
and	O
neck	O
cancer	O
;	O
however	O
,	O
the	O
clinical	O
significance	O
of	O
HPV	O
infection	O
on	O
the	O
pathogenesis	O
of	O
oral	O
cavity	O
squamous	O
cell	O
carcinoma	O
(	O
OSCC	O
)	O
is	O
still	O
uncertain	O
.	O
The	O
study	O
recruited	O
103	B-Study_Cohort
patients	I-Study_Cohort
with	I-Study_Cohort
pathological	I-Study_Cohort
early	I-Study_Cohort
-	I-Study_Cohort
stage	I-Study_Cohort
OSCC	I-Study_Cohort
between	O
March	B-Study_Time
1997	I-Study_Time
and	I-Study_Time
December	I-Study_Time
2003	I-Study_Time
from	O
Chang	O
Gung	O
Memorial	O
Hospital	O
,	O
Taiwan	B-Study_Location
.	O

Tumor	O
specimens	B-HPV_Sample_Type
were	O
HPV	O
-	O
genotyped	O
by	O
the	O
EasychipVR	O
HPV	O
Blot	O
method	O
.	O

Clinical	O
association	O
study	O
was	O
performed	O
by	O
using	O
chi	O
-	O
square	O
,	O
Kaplan	O
-	O
Meier	O
,	O
and	O
logrank	O
tests	O
.	O
Thirty	O
-	O
one	O
patients	O
(	O
30	O
.	O
1	O
%	O
)	O
were	O
positive	O
for	O
HPV	O
infection	O
.	O

The	O
most	O
frequent	O
HPV	O
types	O
were	O
types	O
16	O
(	O
16	O
patients	O
,	O
51	O
.	O
6	O
%	O
)	O
and	O
18	O
(	O
seven	O
patients	O
,	O
22	O
.	O
6	O
%	O
)	O
.	O

HPV	O
infection	O
was	O
not	O
associated	O
with	O
tumor	O
aggressiveness	O
(	O
pathological	O
tumor	O
stage	O
or	O
differentiation	O
status	O
)	O
,	O
risk	O
exposure	O
(	O
alcohol	O
,	O
cigarette	O
,	O
or	O
areca	O
quid	O
chewing	O
habit	O
)	O
,	O
or	O
the	O
treatment	O
outcome	O
(	O
disease	O
-	O
free	O
survival	O
or	O
overall	O
survival	O
)	O
.	O

However	O
,	O
infection	O
with	O
HPV	O
-	O
18	O
was	O
associated	O
with	O
the	O
occurrence	O
of	O
a	O
second	O
primary	O
cancers	O
(	O
Pâ€ƒ=â€ƒ0	O
.	O
033	O
)	O
,	O
indicating	O
the	O
infection	O
of	O
HPV	O
in	O
OSCC	O
enhances	O
the	O
susceptibility	O
of	O
developing	O
secondary	O
malignancy	O
.	O
There	O
are	O
30	O
%	O
of	O
the	O
patients	O
with	O
OSCC	O
infected	O
with	O
HPV	O
,	O
with	O
most	O
high	O
-	O
risk	O
types	O
.	O

HPV	O
-	O
18	O
infection	O
may	O
enhance	O
the	O
susceptibility	O
of	O
second	O
primary	O
tumors	O
.	O

Large	O
scale	O
of	O
validation	O
study	O
will	O
be	O
needed	O
to	O
confirm	O
this	O
result	O
.	O

%	O
%	O
MATERIALS	O
AND	O
METHODS	O

Patients	O
,	O
tissue	B-HPV_Sample_Type
specimens	I-HPV_Sample_Type
,	O
and	O
clinical	O
diagnosis	O

This	O
study	O
was	O
approved	O
by	O
the	O
Institutional	O
Review	O
Board	O
of	O
Chang	O
Gung	O
Memorial	O
Hospital	O
.	O

We	O
recruited	O

103	B-Study_Cohort
patients	I-Study_Cohort
with	I-Study_Cohort
pathological	I-Study_Cohort
early	I-Study_Cohort
-	I-Study_Cohort
stage	I-Study_Cohort
oral	I-Study_Cohort
cavity	I-Study_Cohort
cancer	I-Study_Cohort
who	O
had	O
been	O
treated	O
between	O
March	B-Study_Time
1997	I-Study_Time
and	I-Study_Time
December	I-Study_Time
2003	I-Study_Time
at	O
Chang	O
Gung	O
Memorial	O
Hospital	O
,	O
Lin	O
-	O
Kuo	O
,	O
Taiwan	B-Study_Location
.	O

The	O
mean	O
age	O
of	O
the	O
103	O
recruited	O
patients	O
was	O
49	O
.	O
4	O
years	O
(	O
range	O
,	O
26–81	O
years	O
)	O
(	O
Table	O
1	O
)	O
.	O

Most	O
tumors	O
were	O
located	O
in	O
the	O
tongue	O
and	O
cheek	O
.	O

Of	O
the	O
103	O
tumors	O
,	O
43	O
(	O
41	O
.	O
7	O
%	O
)	O
were	O
stage	O
I	O
and	O
60	O
(	O
58	O
.	O
3	O
%	O
)	O
were	O
stage	O
II	O
.	O

The	O
median	O
follow	O
-	O
up	O
period	O
was	O
41	O
months	O
.	O

All	O
patients	O
provided	O
written	O
informed	O
consent	O
for	O
their	O
participation	O
and	O
were	O
interviewed	O
(	O
before	O
surgery	O
)	O
by	O
a	O
well	O
-	O
trained	O
interviewer	O
.	O

The	O
questionnaire	O
used	O
in	O
the	O
interview	O
sought	O
information	O
on	O
demographic	O
data	O
and	O
on	O
current	O
behaviors	O
and	O
past	O
histories	O
of	O
cigarette	O
smoking	O
,	O
alcohol	O
drinking	O
,	O
and	O
areca	O
quid	O
chewing	O
.	O

The	O
deﬁnitions	O
of	O
habitual	O
uses	O
are	O
cigarette	O
smoking	O
:	O
over	O
ﬁve	O
packages	O
per	O
week	O
,	O
alcohol	O
drinking	O
:	O
over	O
seven	O
bottles	O
per	O
week	O
,	O
betel	O
quid	O
chewing	O
:	O
over	O
100	O
grains	O
per	O
week	O
,	O
continuously	O
uses	O
for	O
over	O
1	O
year	O
.	O

All	O
patients	O
underwent	O
extensive	O
presurgical	O
evalua	O
-	O
tions	O
,	O
which	O
included	O
a	O
medical	O
history	O
and	O
complete	O
physical	O
examination	O
,	O
complete	O
blood	O
count	O
and	O
routine	O
blood	O
biochemistry	O
,	O
CT	O
and	O
⁄	O
or	O
MRI	O
scans	O
of	O
the	O
head	O
and	O
neck	O
,	O
chest	O
radiographs	O
,	O
bone	O
scan	O
,	O
and	O
liver	O

Table	O
1	O
Characteristics	O
of	O
the	O
103	O
patients	O
with	O
oral	O
cavity	O
squamous	O
cell	O
carcinoma	O
(	O
OSCC	O
)	O

Characteristic	O
N	O
(	O
%	O
)	O

Age	O
(	O
year	O
)	O

Mean	O
±	O
s	O
.	O
d	O
.	O
49	O
.	O
4	O
±	O
10	O
.	O
9	O

Range	O
26–81	O

Site	O
of	O
primary	O
tumor	O
[	O
No	O
.	O

of	O
patients	O
(	O
%	O
)	O
]	O

Tongue	O
60	O
(	O
58	O
.	O
3	O
)	O

Mouth	O
ﬂoor	O
5	O
(	O
4	O
.	O
9	O
)	O

Lip	O
1	O
(	O
1	O
.	O
0	O
)	O

Buccal	O
mucosa	O
22	O
(	O
21	O
.	O
4	O
)	O

Alveolar	O
ridge	O
10	O
(	O
9	O
.	O
7	O
)	O

Hard	O
palate	O
2	O
(	O
1	O
.	O
9	O
)	O

Retromolar	O
trigone	O
3	O
(	O
2	O
.	O
9	O
)	O

Pathologic	O
stage	O
[	O
No	O
.	O

of	O
patients	O
(	O
%	O
)	O
]	O

Stage	O
I	O
43	O
(	O
41	O
.	O
7	O
)	O

Stage	O
II	O
60	O
(	O
58	O
.	O
3	O
)	O

Areca	O
quid	O
chewing	O
[	O
No	O
.	O

of	O
patients	O
(	O
%	O
)	O
]	O

Yes	O
79	O
(	O
76	O
.	O
7	O
)	O

No	O
24	O
(	O
23	O
.	O
3	O
)	O

Cigarette	O
smoking	O
[	O
No	O
.	O

of	O
patients	O
(	O
%	O
)	O
]	O

Yes	O
90	O
(	O
87	O
.	O
4	O
)	O

No	O
13	O
(	O
12	O
.	O
6	O
)	O

Alcohol	O
drinking	O
[	O
No	O
.	O

of	O
patients	O
(	O
%	O
)	O
]	O

Yes	O
72	O
(	O
69	O
.	O
9	O
)	O

No	O
31	O
(	O
30	O
.	O
1	O
)	O

ultrasound	O
.	O

The	O
clinical	O
stage	O
was	O
determined	O
according	O
to	O
the	O
AJCC	O
staging	O
system	O
.	O

Clinical	O
histological	O
parameters	O
for	O
each	O
patient	O
were	O
scored	O
according	O
to	O
the	O
recommendations	O
of	O
the	O
Association	O
of	O
Directors	O
of	O
Anatomic	O
and	O
Surgical	O
Pathology	O
(	O
ADASP	O
)	O
for	O
the	O
purpose	O
of	O
reporting	O
any	O
specimens	B-HPV_Sample_Type
containing	O
oral	O
cavity	O
and	O
oropharynx	O
neoplasms	O
(	O
Zarbo	O
et	O
al	O
,	O
2000	O
)	O
.	O

All	O
the	O
patients	O
received	O
radical	O
surgery	O
with	O
curative	O
intent	O
as	O
their	O
primary	O
treatment	O
.	O

Those	O
who	O
received	O
other	O
treatment	O
(	O
such	O
as	O
radiation	O
or	O
chemotherapy	O
)	O
as	O
primary	O
treatment	O
were	O
excluded	O
from	O
our	O
analysis	O
.	O

The	O
deﬁnition	O
for	O
double	O
-	O
cancer	O
or	O
multiple	O
primary	O
tumor	O
in	O
our	O
study	O
is	O
that	O
a	O
tumor	O
that	O
occurs	O
in	O
another	O
subsite	O
separated	O
by	O
a	O
normal	O
mucosa	O
of	O
2	O
cm	O
or	O
more	O
of	O
distance	O
to	O
the	O
primary	O
site	O
.	O

The	O
follow	O
-	O
up	O
period	O
ranged	O
from	O
12	O
to	O
136	O
months	O
(	O
median	O
,	O
41	O
.	O
5	O
months	O
)	O
.	O

There	O
were	O
14	O
cases	O
with	O
local	O
recurrence	O
in	O
which	O
the	O
tumors	O
re	O
-	O
grew	O
in	O
the	O
same	O
tumor	O
subsite	O
of	O
primary	O
lesions	O
.	O

Another	O
12	O
patients	O
had	O
second	O
primary	O
tumor	O
during	O
their	O
follow	O
-	O
up	O
time	O
.	O

Tissue	B-HPV_Sample_Type
samples	I-HPV_Sample_Type
and	O
DNA	O
extraction	O

Ten	O
micrometer	O
sections	O
were	O
cut	O
from	O
the	O
paraﬃn	O
blocks	O
of	O
cancer	O
tissues	B-HPV_Sample_Type
and	O
collected	O
into	O
1	O
.	O
5	O
-	O
ml	O
Eppendorf	O
tubes	O
for	O
DNA	O
extraction	O
.	O

To	O
prevent	O
cross	O
-	O
contamination	O
,	O
each	O
block	O
was	O
cut	O
after	O
a	O
thor	O
-	O
ough	O
cleaning	O
of	O
the	O
microtome	O
blade	O
.	O

Paraﬃn	O
-	O
embed	O
-	O
ded	O
samples	B-HPV_Sample_Type
were	O
placed	O
in	O
xylene	O
for	O
5	O
min	O
and	O
centrifuged	O
at	O
20817	O
g	O
.	O

DNA	O
was	O
extracted	O
using	O
QIA	O
-	O
amp	O
DNA	O
Mini	O
kits	O
(	O
Qiagen	O
,	O
Valencia	O
,	O
CA	O
,	O
USA	O
)	O
.	O

The	O

quality	O
(	O
ratio	O
of	O
absorbance	O
at	O
260	O
nm	O
⁄	O
280	O
nm	O
)	O
and	O

quantity	O
(	O
absorbance	O
at	O
260	O
nm	O
)	O
of	O
the	O
isolated	O
DNA	O
were	O
determined	O
spectrophotometrically	O
.	O

HPV	O
genotyping	O
by	O
EasychipVR	O
HPV	O
blot	O

SPF1	O
⁄	O
GP6t	O
consensus	O
primers	O
were	O
used	O
to	O
amplify	O
a	O
fragment	O
of	O
approximately	O
184	O
bp	O
in	O
the	O
L1	O
open	O
reading	O
frame	O
of	O
HPV	O
(	O
Lai	O
et	O
al	O
,	O
2007	O
;	O
Chao	O
et	O
al	O
,	O
2010	O
)	O
.	O

The	O
resulting	O
15	O
-	O
ll	O
amplimers	O
were	O
hybridized	O
with	O
an	O
EasychipVR	O
HPV	O
Blot	O
nylon	O
membrane	O
(	O
King	O
Car	O
,	O
I	O
-	O
Lan	O
,	O
Taiwan	O
;	O
hereafter	O
HPV	O
Blot	O
)	O
(	O
Huang	O
et	O
al	O
,	O
2006	O
)	O
,	O
on	O
which	O
oligonucleotide	O
probes	O
for	O
38	O
types	O
of	O
HPV	O
[	O
6	O
,	O
11	O
,	O
16	O
,	O
18	O
,	O
26	O
,	O
31	O
,	O
32	O
,	O
33	O
,	O
35	O
,	O
37	O
,	O
39	O
,	O
42	O
,	O
43	O
,	O
44	O
,	O

45	O
,	O
51	O
,	O
52	O
,	O
53	O
,	O
54	O
,	O
55	O
,	O
56	O
,	O
58	O
,	O
59	O
,	O
61	O
,	O
62	O
,	O
66	O
,	O
67	O
,	O
68	O
,	O
69	O
,	O
70	O
,	O

71	O
(	O
CP8061	O
)	O
,	O
72	O
,	O
74	O
,	O
81	O
(	O
CP8304	O
)	O
,	O
82	O
(	O
MM4	O
)	O
,	O
83	O

(	O
MM7	O
)	O
,	O
84	O
(	O
MM8	O
)	O
,	O
and	O
L1AE5	O
]	O
had	O
been	O
immobilized	O
.	O

E6	B-HPV_Lab_Technique
type	I-HPV_Lab_Technique
-	I-HPV_Lab_Technique
speciﬁc	I-HPV_Lab_Technique
PCRs	I-HPV_Lab_Technique
were	O
performed	O
to	O
validate	O
multiple	O
types	O
.	O

Viral	O
characteristics	O
(	O
HPV	O
genotype	O
,	O
high	O
-	O
risk	O
or	O
low	O
-	O
risk	O
type	O
and	O
multiple	O
or	O
single	O
type	O
)	O
of	O
the	O
infection	O
were	O
included	O
in	O
the	O
analyses	O
.	O

If	O
a	O
patient	O
was	O
infected	O
with	O
both	O
high	O
-	O
risk	O
and	O
low	O
-	O
risk	O
types	O
of	O
HPV	O
,	O
this	O
patient	O
was	O
categorized	O
as	O
high	O
-	O
risk	O
group	O
.	O

Statistical	O
analysis	O

The	O
major	O
variables	O
examined	O
were	O
disease	O
-	O
free	O
survival	O
(	O
DFS	O
)	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
.	O

Follow	O
-	O
up	O
time	O
was	O
calculated	O
from	O
the	O
date	O
of	O
hospital	O
admission	O
for	O
surgery	O
until	O
the	O
date	O
of	O
death	O
or	O
last	O
contact	O
.	O

Diﬀer	O
-	O
ences	O
between	O
proportions	O
of	O
HPV	O
-	O
infected	O
patients	O
were	O
determined	O
using	O
the	O
chi	O
-	O
square	O
test	O
.	O

Survival	O
curves	O
were	O
constructed	O
using	O
the	O
Kaplan–Meier	O

Table	O
2	O
Distribution	O
of	O
HPV	O
types	O
in	O
HPV	O
-	O
positive	O
patients	O
(	O
N	O
=	O
31	O
)	O

Table	O
3	O
Associations	O
between	O
HPV	O
infection	O
and	O
clinicopathological	O

811	O

parameters	O
(	O
N	O
=	O
103	O
)	O

Types	O
of	O
HPV	O
infection	O
Number	O
of	O
patients	O
Frequency	O
(	O
%	O
)	O

HPV	O
infection	O

35	O
1	O
3	O
.	O
2	O
Subsites	O

58	O
,	O
66	O
1	O
3	O
.	O
2	O
Overall	O
stage	O

MM4	O
,	O
81	O
1	O
3	O
.	O
2	O

Total	O
31	O

Diﬀerentiation	O

Well	O
(	O
n	O
=	O
51	O
)	O
34	O
(	O
66	O
.	O
7	O
)	O
17	O
(	O
33	O
.	O
3	O
)	O
0	O
.	O
775b	O

Moderate	O
(	O
n	O
=	O
48	O
)	O
35	O
(	O
72	O
.	O
9	O
)	O
13	O
(	O
27	O
.	O
1	O
)	O

Poor	O
(	O
n	O
=	O
4	O
)	O
3	O
(	O
74	O
.	O
58	O
)	O
1	O
(	O
25	O
.	O
42	O
)	O

method	O
and	O
compared	O
using	O
the	O
logrank	O
test	O
.	O

All	O
data	O

Betel	O
quid	O
chewing	O

were	O
analyzed	O
by	O
the	O
SPSS	O
14	O
.	O
0	O
statistical	O
package	O
(	O
SPSS	O
,	O
Chicago	O
,	O
IL	O
,	O
USA	O
)	O
.	O

All	O
tests	O
were	O
2	O
-	O
sided	O
,	O
and	O
a	O
P	O
value	O
of	O
<	O
0	O
.	O
05	O
was	O
considered	O
statistically	O
signiﬁcant	O
.	O

